Patient Guide: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 196 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT02453282
Status: ACTIVE_NOT_RECRUITING
Condition: Non-Small-Cell Lung Carcinoma NSCLC
Phase: PHASE3

Where You Can Participate

This study is available at 196 locations across the country.

Top locations include:
  • • Scottsdale, Arizona
  • • Tucson, Arizona
  • • Yuma, Arizona
  • • And 193 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) - Join Clinical Trial NCTNCT02453282

How to Join This Clinical Trial - NCTNCT02453282

Learn how to participate in this PHASE3 trial studying an investigational therapy for Non-Small-Cell Lung Carcinoma NSCLC. Current status: ACTIVE_NOT_RECRUITING.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Non-Small-Cell Lung Carcinoma NSCLC. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Non-Small-Cell Lung Carcinoma NSCLC
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
ACTIVE_NOT_RECRUITING
Study Identifier
NCTNCT02453282 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 196 locations. Find a study site near you:

Clinical Research Site

Scottsdale, Arizona 85259 - United States

Status: Contact for availability

Clinical Research Site

Tucson, Arizona 85715 - United States

Status: Contact for availability

Clinical Research Site

Yuma, Arizona 85364 - United States

Status: Contact for availability

Clinical Research Site

Bakersfield, California 93309 - United States

Status: Contact for availability

Clinical Research Site

Fullerton, California 92835 - United States

Status: Contact for availability

Clinical Research Site

La Jolla, California 92093 - United States

Status: Contact for availability

Clinical Research Site

Los Angeles, California 90024 - United States

Status: Contact for availability

Clinical Research Site

Los Angeles, California 90073 - United States

Status: Contact for availability

Clinical Research Site

Redondo Beach, California 90277 - United States

Status: Contact for availability

Clinical Research Site

Sacramento, California 95817 - United States

Status: Contact for availability

And 186 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Non-Small-Cell Lung Carcinoma NSCLC:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships